Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
A new study conducted by Baylor College of Medicine and presented at the American College of Cardiology Annual Scientific Session as well as the World Congress of Cardiology shows that an oral PCSK9 inhibitor called MK-0616...
Read Full NewsMind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Benjamin Tolchin, MD, MS, FAAN. [LISTEN TIME: 23 minutes]
Alixorexton, an oral investigational selective orexin 2 receptor agonist, is currently in development for the treatment of narcolepsy type 1 and type 2, and idiopathic hypersomnia.
1.
An inoperable locally advanced NSCLC trial dubbed "Practice Changing".
2.
Study finds 1 in 12 patients labeled as having 'benign' results actually had high-risk prostate cancer
3.
Biomarker panel offers hope for early pancreatic cancer detection
4.
For patients with clear cell renal cell carcinoma, a new PET agent allows for same-day imaging.
5.
In leukemia, allogeneic HCT is beneficial following primary induction failure.
1.
Unveiling the Secrets of Early Cancer: Emerging Strategies to Decipher Its Biology
2.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
3.
The benefits and risks of taking fludrocortisone for adrenal insufficiency
4.
Revolutionizing Thyroid Cancer: Advances in Molecular Genetics and Personalized Treatment Approaches
5.
Revolutionizing Cancer Care: The Transformative Role of AI and Data Science in Oncology
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion
3.
Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment
4.
Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge